Translational Aspects of the Mammalian Target of Rapamycin Complexes in Diabetic Nephropathy

Alaa Abou Daher1, Sahar Alkhansa1,2, William S Azar1,2,3

  • 1Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine and Medical Center, American University of Beirut, Beirut, Lebanon.

Insights

Diabetic nephropathy (DN) treatments remain elusive. This review highlights the mammalian target of rapamycin (mTOR) pathway

Area of Science:

  • Cell Biology
  • Metabolism
  • Renal Medicine

Background:

  • Diabetic nephropathy (DN) lacks direct treatments, necessitating mechanistic understanding for drug discovery.
  • The mammalian target of rapamycin (mTOR) pathway regulates key cellular processes implicated in DN.
  • Kidney cells depend on autophagy for integrity, but diabetes disrupts this process.

Purpose of the Study:

  • To review the role of the mTOR pathway in diabetes-induced kidney injury.
  • To elucidate mechanisms linking mTOR signaling to DN pathogenesis.
  • To identify mTOR as a potential therapeutic target for DN.

Main Methods:

  • Literature review of studies investigating mTOR signaling in diabetic kidney disease.
  • Analysis of evidence linking mTOR hyperactivation to insulin resistance, oxidative stress, and autophagy inhibition.
  • Synthesis of current knowledge on the interplay between oxidative stress, autophagy, and mTOR in DN.

Main Results:

  • mTOR hyperactivation is implicated in diabetes-induced kidney injury.
  • mTOR signaling contributes to DN by increasing insulin resistance and oxidative stress.
  • mTOR pathway dysregulation inhibits essential autophagy processes in the kidney.

Conclusions:

  • mTOR signaling is a key player in the development of diabetic nephropathy.
  • Targeting the mTOR pathway may offer a novel therapeutic strategy for DN.
  • Further research into Akt/mTOR signaling is crucial for understanding DN mechanisms.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
Post-translational Translocation of Proteins to the RER01:27

Post-translational Translocation of Proteins to the RER

A sizable fraction of proteins destined for ER are first synthesized in the cell cytosol and then transported across the ER membrane–a process called post-translational translocation. Similar to cotranslationally translocated proteins, these proteins also use the Sec translocon complex to enter the ER lumen.
Targeting proteins to the ER
Hsp40 and Hsp70 chaperone molecules bind the translated proteins in the cytosol to prevent their folding. The chaperone binding helps to keep the signal...
6.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.2K